Assessing the rationality of using statins in primary prevention of atherosclerotic coronary disease risk in patients with type 2 diabetes based on the ASCVD-10 scale at Hai Phong International General Hospital in 2020

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is the main clinical manifestation of cardiovascular disease, contributing greatly to the mortality rate of patients with diabetes. In 2019, the American Heart Association (ACC/AHA) released guidelines for cholesterol - lowering treatments to reduce cardiovascular risk from atherosclerosis. Therefore, we conducted a study on 2781 patients with type 2 diabetes to evaluate the rationality of using statins in the primary prevention of atherosclerotic coronary disease risk in this group of patients. type 2 diabetes based on the ASCVD - 10 scale at Hai Phong International General Hospital in 2020 according to the ACC/AHA recommendations in 2019. The results showed that 51% of patients 40 - 75 years old received only statins. Patients assigned to low-intensity statins accounted for the highest proportion with 57.0%, average statin intensity accounted for 39.5% and the lowest was high-intensity statin therapy with 3.5%. 59.8% of patients with type 2 diabetes in the 40 - 75 years old group at the hospital had rationally used statins as recommended by the ACC/AHA 2019. The results show the urgency and need to make efforts to ensure An increasing number of diabetic patients are receiving appropriate statin therapy for the primary prevention of atherosclerotic coronary disease risk.